Rapid Micro Biosystems to Showcase Automation Solutions at H.C. Wainwright Global Investment Conference
ByAinvest
Wednesday, Sep 3, 2025 4:30 am ET1min read
RPID--
Rapid Micro Biosystems specializes in providing mission-critical automation solutions for healthcare product manufacturing. The company's flagship product, the Growth Direct system, automates and modernizes the microbial quality control (MQC) testing workflows used in large-scale pharmaceutical manufacturing operations. This system brings the quality control lab to the manufacturing floor, enhancing efficiency, accuracy, and compliance with data integrity regulations [1][2].
The company's headquarters are located in Lexington, Massachusetts, with U.S. manufacturing in Lowell, Massachusetts. Additionally, Rapid Micro Biosystems has global locations in Switzerland, Germany, and the Netherlands. For more information, investors can visit the company's website at [www.rapidmicrobio.com](http://www.rapidmicrobio.com) or follow the company on X (formerly known as Twitter) at [@rapidmicrobio](http://twitter.com/rapidmicrobio) or on LinkedIn [1][2].
References:
[1] https://www.globenewswire.com/news-release/2025/09/02/3143190/33206/en/Rapid-Micro-Biosystems-to-Present-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html
[2] https://www.biospace.com/press-releases/rapid-micro-biosystems-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference
Rapid Micro Biosystems will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. The company specializes in automation solutions for healthcare product manufacturing and will showcase its innovative technologies that facilitate efficient manufacturing and safe release of healthcare products. Investors can access a live webcast through the company's investor relations website.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID), an innovative life sciences technology company, has announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York, NY. The presentation is scheduled for Tuesday, September 9, 2025, at 11:00 a.m. ET. Investors and financial professionals can access a live webcast of the presentation through the company's investor relations website at [https://investors.rapidmicrobio.com/](https://investors.rapidmicrobio.com/) [1][2].Rapid Micro Biosystems specializes in providing mission-critical automation solutions for healthcare product manufacturing. The company's flagship product, the Growth Direct system, automates and modernizes the microbial quality control (MQC) testing workflows used in large-scale pharmaceutical manufacturing operations. This system brings the quality control lab to the manufacturing floor, enhancing efficiency, accuracy, and compliance with data integrity regulations [1][2].
The company's headquarters are located in Lexington, Massachusetts, with U.S. manufacturing in Lowell, Massachusetts. Additionally, Rapid Micro Biosystems has global locations in Switzerland, Germany, and the Netherlands. For more information, investors can visit the company's website at [www.rapidmicrobio.com](http://www.rapidmicrobio.com) or follow the company on X (formerly known as Twitter) at [@rapidmicrobio](http://twitter.com/rapidmicrobio) or on LinkedIn [1][2].
References:
[1] https://www.globenewswire.com/news-release/2025/09/02/3143190/33206/en/Rapid-Micro-Biosystems-to-Present-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html
[2] https://www.biospace.com/press-releases/rapid-micro-biosystems-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet